Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for tags : Designation save search
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 4.91%
H: 11.36%
C: 0.67%
drug treatment designation for grants leukemia
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
LXEO | $11.995 -0.62% -0.63% 87K
|
|
| O: 5.32%
H: 0.0%
C: -2.63%
lx2006 fda candidate granted treatment designation for therapeutics therapy
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
SNGX | $0.4233 -2.76% -2.83% 1M
|
Health Technology
|
| O: 75.34%
H: 37.73%
C: -30.58%
fda drug marburg infection designation for grants
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
SNGX | $0.4233 -2.76% -2.83% 1M
|
Health Technology
|
| O: 3.67%
H: 0.46%
C: -19.02%
fda drug infection designation for grants
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Published: 2024-04-11 (Crawled : 13:00) - globenewswire.com
CADL | $5.17 -5.31% -5.61% 520K
|
|
| O: 25.49%
H: 23.75%
C: 13.75%
can-2409 fda drug cancer pancreatic treatment designation for therapeutics
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
PTCHF | $2.78 19.97% 560
|
n/a
|
| O: 4.65%
H: 0.0%
C: 0.0%
lyt-200 fda designation for
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.06%
H: 0.47%
C: -0.03%
fda device disease test granted blood designation for alzheimer's roche
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Published: 2024-04-09 (Crawled : 12:30) - globenewswire.com
LSTA | $2.85 -5.82% 2K
|
Manufacturing
|
| O: 0.34%
H: 9.62%
C: 3.78%
fda drug granted treatment designation for therapeutics
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
SYRS | $4.54 -3.81% -3.96% 260K
|
Health Technology
|
| O: 2.16%
H: 23.21%
C: 16.03%
fda treatment designation for aml
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
SLDB | $8.7 -6.05% -6.44% 110K
|
Health Technology
|
| O: -9.02%
H: 0.0%
C: -7.65%
sgt-003 fda rare candidate disease designation duchenne therapy
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
MDXG | $6.3 2.27% 2.22% 690K
|
Health Technology
|
| O: 0.26%
H: 2.29%
C: -0.39%
axiofill fda update designation
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 0.0%
H: 0.03%
C: -5.2%
tnx-2900 fda rare disease treatment pharmaceuticals designation
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Published: 2024-03-21 (Crawled : 12:00) - globenewswire.com
LSTA | $2.85 -5.82% 2K
|
Manufacturing
|
| O: 0.32%
H: 9.68%
C: 8.06%
fda rare disease granted treatment designation therapeutics
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
Published: 2024-03-20 (Crawled : 13:00) - globenewswire.com
CELU | News F | $3.09 -3.74% -3.88% 24K
|
|
| O: 4.02%
H: 0.74%
C: 0.74%
pda-002 fda drug designation
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
Published: 2024-03-20 (Crawled : 11:00) - globenewswire.com
CABA | $13.31 -4.72% -4.96% 1.2M
|
Health Technology
|
| O: 0.0%
H: 1.44%
C: 0.67%
caba-201 fda drug granted sclerosis treatment designation
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
Published: 2024-03-14 (Crawled : 12:00) - globenewswire.com
KROS | $58.345 -1.03% -1.04% 350K
|
Health Technology
|
| O: -0.95%
H: 0.34%
C: -3.27%
ker-050 fda designation therapeutics
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
Published: 2024-03-13 (Crawled : 20:00) - prnewswire.com
PSTX | $2.02 1.0% 0.99% 640K
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: -4.14%
fda drug granted treatment designation therapeutics
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
Published: 2024-03-13 (Crawled : 11:00) - globenewswire.com
PCRX | $26.24 0.54% 0.53% 450K
|
Health Technology
|
| O: 0.03%
H: 1.24%
C: -0.92%
pcrx-201 osteoarthritis granted treatment designation therapy
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
Published: 2024-03-12 (Crawled : 11:00) - biospace.com/
KALV | $11.59 0.78% 0.78% 350K
|
Health Technology
|
| O: -1.83%
H: 1.63%
C: -2.88%
sebetralstat pharmaceuticals designation
US FDA grants Orphan Drug Designation for iOnctura's first-in-class autotaxin cancer therapy
Published: 2024-03-07 (Crawled : 08:00) - prnewswire.com
PPRUF | $358.55 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -1.57%
H: 1.91%
C: 0.49%
PPRUY | $36.0023 -0.11% 220K
|
Manufacturing
|
| O: -0.6%
H: 1.23%
C: 1.17%
fda drug cancer designation grants therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.